RenovoRx, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
RenovoRx reported Q2 2026 revenue of $909K (up 61% QoQ, 115% YoY from $422K in Q2 2025), with 21 active commercial cancer center customers (up from 16 in Q1 2026) and a pipeline of 63 total centers. The company raised full-year 2026 revenue guidance to $3.75M–$4.25M (from $3.0M–$4.0M), implying 241–286% YoY growth versus $1.1M in 2025. Cash stood at $9.5M as of June 30, 2026 (down from $12.4M March 31, 2026), with 45.1M shares outstanding; management projects cash-flow break-even in Q4 2027 at ~$5M quarterly revenue run-rate.
Why this rating
Strong revenue acceleration and customer growth meaningful relative to $26.6M market cap; breakeven path credible if guidance holds, but company remains unprofitable and cash-constrained.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.